- Home
- REE vs TCRX Comparison
REE vs TCRX Comparison
Compare REE & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- TCRX
- Stock Information
- Founded
- REE 2011
- TCRX 2018
- Country
- REE Israel
- TCRX United States
- Employees
- REE N/A
- TCRX N/A
- Industry
- REE Auto Manufacturing
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- TCRX Health Care
- Exchange
- REE Nasdaq
- TCRX Nasdaq
- Market Cap
- REE 67.1M
- TCRX 67.9M
- IPO Year
- REE N/A
- TCRX 2021
- Fundamental
- Price
- REE $2.51
- TCRX $1.44
- Analyst Decision
- REE Strong Buy
- TCRX Strong Buy
- Analyst Count
- REE 3
- TCRX 6
- Target Price
- REE $12.50
- TCRX $9.83
- AVG Volume (30 Days)
- REE 221.0K
- TCRX 520.8K
- Earning Date
- REE 05-29-2025
- TCRX 05-12-2025
- Dividend Yield
- REE N/A
- TCRX N/A
- EPS Growth
- REE N/A
- TCRX N/A
- EPS
- REE N/A
- TCRX N/A
- Revenue
- REE $626,000.00
- TCRX $2,816,000.00
- Revenue This Year
- REE N/A
- TCRX $47.30
- Revenue Next Year
- REE $21,152.58
- TCRX $74.30
- P/E Ratio
- REE N/A
- TCRX N/A
- Revenue Growth
- REE N/A
- TCRX N/A
- 52 Week Low
- REE $2.35
- TCRX $1.02
- 52 Week High
- REE $11.72
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- REE 28.92
- TCRX 49.74
- Support Level
- REE $2.31
- TCRX $1.02
- Resistance Level
- REE $2.90
- TCRX $1.36
- Average True Range (ATR)
- REE 0.33
- TCRX 0.16
- MACD
- REE 0.13
- TCRX 0.05
- Stochastic Oscillator
- REE 23.28
- TCRX 77.78
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is developing REEcorner technology which packs critical vehicle components into a single compact module positioned between the chassis and the wheel as well as building commercial Electric Vehicles (EV) leveraging REEcorner technology. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.